Home > Inhibitors & Agonists > Tyrosine Kinase > Syk

Syk

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC9632 BAY 61-3606 (dihydrochloride) Featured BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
DC10660 BAY 61-3606 free base Featured BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
DC7948 PRT-060318(PRT318) Featured PRT-060318 is a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.
DC1014 R406 free base Featured R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.
DC8733 R406 Featured R406 is a potent Syk inhibitor with IC50 of 41 nM and also potently inhibits Flt3.
DC9841 Fostamatinib(R788) Featured R788 (Fostamatinib), a prodrug of the active metabolite R406, is a potent Syk inhibitor with IC50 of 41 nM.
DC1013 R788 disodium (Fostamatinib) Featured R935788 (Fostamatinib disodium, R788) is a Syk inhibitor with IC50 of 41 nM.
DC9759 RO0921 Featured RO0921 is a novel, potent SYK inhibitor.
DC10523 TAK-659 HCl Featured TAK-659 hydrochloride is a potent, selective and orally available spleen tyrosine kinase (Syk) inhibitor with an IC50 of 3.2 nM.
DC28254 Lanraplenib monosuccinate Featured Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
DC28255 Lanraplenib succinate Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
DC40367 Syk-IN-1 Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM.
DC40848 SRX3207 Featured SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses anti-tumor activity.
DC41092 Cerdulatinib hydrochloride Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.
DC42006 Syk Kinase Peptide Substrate, Biotin labeled Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.
DC42007 Syk Kinase Peptide Substrate Syk Kinase Peptide Substrate is a Syk kinase peptide substrate.
DC42425 Syk-IN-4 Syk-IN-4 is a potent, selective and orally bioavailable SYK with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.
DC48025 Cevidoplenib dimesylate Featured Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.
DC48364 Sovleplenib Sovleplenib is a potent spleen tyrosine kinase (Syk) inhibitor, extracted from patent WO2012167733 A1.
DC48946 SYK/JAK-IN-1 SYK/JAK-IN-1 is dual SYK/JAK inhibitor with IC50s of <5 nM for SYK and JAK2, respectively.
DC70447 GSK143 GSK143 is a highly potent, selective, orally efficacious Syk inhibitor with pIC50 of 7.5, >600-fold selective over ZAP-70; inhibits anti-IgM induced Erk1/2 phosphorylation in Ramos cells with pIC50 of 7.1, and anti-IgM induced CD69 surface expression in primary B cells with pIC50 of 6.6; shows good efficacy in the rat Arthus model.
DC70457 GSK2646264 Featured GSK2646264 (GSK-2646264) is a potent, selective Spleen Tyrosine Kinase (Syk) inhibitor with pIC50 of 7.1, >300-fold selectivity over Autota B; inhibits anti-IgM induced Erk1/2 phosphorylation in Ramos B cells with pIC50 of 6.7.
DC74422 BI 1342561 BI 1342561 is a novel potent and selective SYK inhibitor developed to treat severe asthma.
DC74423 BI 894416 BI 894416 is a novel potent and selective SYK inhibitor developed to treat severe asthma.
DC74424 MRL-SYKi MRL-SYKi is a potent, selective inhibitor of Syk (Spleen tyrosine kinase) with IC50 of <100 nM, also potently inhibits ZAP70 (24 nM in vitro).
DC74425 MTX-216 MTX-216 (MTX216) is a dual PI3K/EGFR inhibitor that blocks neurofibromin 1 loss of function (NF1LoF) melanoma cell growth in vitro and in vivo, suppresses the activity of SYK kinase with IC50 of 281 nM.
DC74426 RDN009 RDN009 (RDN-009) is a potent, selective, and covalent ZAP-70 kinase inhibitor with IC50 of 55 nM.
DC74427 RDN2150 RDN2150 is a potent, selective and covalent ZAP-70 inhibitor with IC50 of 14.6 nM, shows no significant activity against Syk, covalently binds to the C346 residue of ZAP-70.
<PrevNext >

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia